Cantor Fitzgerald Assumes Poseida Therapeutics, Inc (PSTX) at Overweight

May 13, 2022 4:18 PM EDT
Get Alerts PSTX Hot Sheet
Price: $2.10 +3.96%

Rating Summary:
    6 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 4 | Down: 15 | New: 18
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Cantor Fitzgerald analyst Jennifer Kim assumes coverage on Poseida Therapeutics, Inc (NASDAQ: PSTX) with a Overweight rating and a price target of $24.00.

The analyst commented, "PSTX is a clinical-stage biopharmaceutical company that is developing next-generation cell and gene therapies designed to overcome the key limitations of current cell and gene therapies (e.g., cost/accessibility, safety/tolerability, potency/durability). We believe the key focuses for PSTX this year are on the company's two Phase 1 fully allogeneic (off-the-shelf) CAR-T candidates, P-BCMA-ALLO1 (relapsed/refractory multiple myeloma, r/r MM) and P-MUC1C-ALLO1 (solid tumors), with initial clinical data for each guided to 2H22."

For an analyst ratings summary and ratings history on Poseida Therapeutics, Inc click here. For more ratings news on Poseida Therapeutics, Inc click here.

Shares of Poseida Therapeutics, Inc closed at $1.87 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Cantor Fitzgerald